ALCESTER, England, November 3,
2014 /PRNewswire/ --
~ Funding Round Led by ALIAD the
Venture Vehicle of Air Liquide ~
Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a
pioneering developer of advanced haemodialysis systems, today
announces that it has closed a fundraising of approximately £27
million. The funding round was led by ALIAD, the venture capital
investment vehicle of Air Liquide SA (Paris: AI), and included
participation by new investor Seventure Partners, as well as
existing investors Wellington Partners, Seroba Kernel, NBGI
Ventures, b-to-v Partners and IMI plc (LSE: IMI).
Funds will be used to support the clinical introduction and
commercial launch of SC+, Quanta's advanced haemodialysis system.
SC+ is the only portable, compact haemodialysis system in
development providing the clinical efficacy and high flow rates
comparable to in-centre machines. SC+ is designed to provide a
significant change in the way dialysis patients are treated, with
its unique cartridge-based design that allows greater ease-of-use
and treatment flexibility, whether in-centre or in the home.
John E. Milad, Chief Executive
Officer of Quanta, said, "This
funding will support our
activities as
we progress SC+ towards clinical
introduction and
subsequent commercial launch. We
are delighted to welcome our new investors
ALIAD and
Seventure Partners, who share our vision
of improving renal care for
patients and healthcare professionals."
About Quanta
Quanta is developing advanced haemodialysis systems for use in
the clinic and the home. The Company's cartridge-based solution SC+
is the only portable, compact haemodialysis system with the
clinical efficacy and high flow rates of traditional machines.
SC+ is designed to offer ease-of-use and flexibility,
facilitating self-care and supporting dialysis patients across the
entire continuum of care.
Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008
as a spin out from the FTSE 100 engineering company IMI plc.
Funding has been provided by a group of leading venture capital
investors specialised in healthcare: initially NBGI Ventures,
Wellington Partners, Seroba Kernel and b-to-v Partners, and more
recently ALIAD and Seventure Partners.
Quanta is dedicated to creating a paradigm shift in renal care
and to improving the lives of dialysis patients.
For more information please visit: http://www.quantafs.com
About End Stage Renal Disease and Haemodialysis
Lifestyle choices, modern diet and increased life expectancy are
all negatively impacting renal health across the globe, and End
Stage Renal Disease (ESRD) affects millions of patients worldwide.
Haemodialysis is a life-saving treatment delivered to an estimated
2 million people with ESRD globally-with this figure expected
to double in the next decade.
At present, haemodialysis is primarily provided by specialist
clinics and centres. However this means that the patient is not in
control of when they can dialyse. It is clinically demonstrated
that more frequent dialysis and/or longer treatment sessions
improve outcomes and quality of life for patients, and a number of
studies have shown that 30-40% of patients would be capable of
performing self-dialysis.
Issues of patient benefit, cost and clinic capacity are driving
the growth of home and self-care modalities of haemodialysis, but a
major factor limiting the growth of self-care and home
haemodialysis is the lack of convenient, portable and easy-to-use
dialysis systems. SC+ addresses these issues and puts the patient
at the centre, allowing them to take greater control of their
treatment.
For more information about Quanta, please contact:
Quanta
John E. Milad,
Chief Executive Officer
T: +44-(0)1789-400043
Consilium Strategic Communications
Amber Bielecka / Mary-Jane Elliott / Matthew Neal / Lindsey
Neville
T: +44-(0)203-709-5708
E: quanta@consilium-comms.com
SOURCE Quanta